Design and synthesis of HCV agents with sequential triple inhibitory potentials.

Research paper by Tianmin T Zhu, Mahdi B MB Fawzi, Michael M Flint, Fangming F Kong, Jan J Szeliga, Russ R Tsao, Anita Y M AY Howe, Weitao W Pan

Indexed on: 27 Jul '10Published on: 27 Jul '10Published in: Bioorganic & Medicinal Chemistry Letters


The union of HCV-796, a potent selective HCV NS5B polymerase inhibitor, and Ribavirin, a molecule with activities against a wide spectrum of viruses, resulted in a class of new anti-HCV agents with a sequential triple inhibitory mechanism.